David is a General Partner with Ampersand Capital. Prior to joining Ampersand in 2010, David spent six years with Covington Associates, a specialty investment bank focused on middle-market M&A in the healthcare sector. Prior to Covington, he spent five years as a consultant for Boston Healthcare Associates. David’s current and past board seats include Genezen, ArrantaBio, StageBio, Protogene, BioClinica, BrammerBio, Vernal Biosciences and Vibalogics.
David holds a B.Sc. from the University of Aberdeen, Scotland, a Ph.D. in Immunology from the University of Sheffield, England, and a M.B.A. from Babson College, Wellesley, MA.